The Drug Enforcement Administration (DEA) announced changes in rules regulating prescribing of buprenorphine for opioid use disorder (OUD).
Section 1262 of the Consolidated Appropriations Act, 2023, removes the federal requirement for practitioners to have a DATA-Waiver to prescribe buprenorphine for treatment of OUD.
Effective June 21, 2023:
- DATA-Waiver registration is no longer required to treat patients with buprenorphine for OUD.
- All prescriptions for buprenorphine require only a standard DEA registration number.
- There are no limits or patient caps on the number of patients a prescriber may treat for OUD with buprenorphine.
- Existing state laws or regulations remain in effect.
Beginning June 27, 2023, all DEA-registered practitioners will be required to check a box on their online DEA registration form affirming they have completed a one-time eight-hour training on treatment and management of patients with opioid or other substance use disorders.
These changes could improve access to medical treatment for OUD for pregnant persons in Wisconsin.
For more information on the 8-hour training requirement, click here.
For more information, visit the Substance Abuse and Mental Health Administration’s FAQ.